News: ZIOPHARM Drug Designated for Malignant Glioma $ZIOP

ZIOPHARM Oncology, Inc., a bio pharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with malignant Glioma. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression […]

News: ZIOPHARM Drug Designated for Malignant Glioma $ZIOP Read More »